Who should be accountable when an AI workflow affects patient care?

Why This Matters for Security Teams

When an AI workflow affects patient care, accountability is not just a governance label. It determines who can approve the workflow, who monitors for drift or unsafe outputs, and who can stop use when risk changes. Healthcare teams often underestimate how quickly a clinical support workflow becomes a safety issue once it influences triage, prioritisation, documentation, or treatment decisions. That makes clear ownership a control requirement, not an administrative preference.

Current guidance suggests aligning responsibility to the business owner, the clinical leader, and the governance function, with IT supporting implementation rather than carrying the decision burden alone. That approach fits the control logic in NIST SP 800-53 Rev 5 Security and Privacy Controls, where accountability, authorisation, auditability, and incident response are deliberately separated. For AI workflows, the same principle applies to model changes, prompts, training data, and downstream clinical use.

Practitioners often get this wrong by treating the system as a technology deployment with a general IT owner, then discovering too late that no one had authority to pause the workflow after unsafe behaviour appeared in production.

How It Works in Practice

Accountability should be mapped to the actual decision points in the workflow, not to the team that procured the tool. In practice, that means defining who owns clinical suitability, who owns technical operation, who owns data and model governance, and who has authority to suspend use. For patient-facing or care-influencing systems, the accountable chain should include a named clinical sponsor, a risk or governance lead, and operational owners for security and service management.

That chain should be documented before go-live and maintained as the workflow changes. A useful operational pattern is to separate approval, monitoring, and override responsibilities:

• Approval covers whether the AI workflow is acceptable for a defined clinical use case.
• Monitoring covers output quality, bias, drift, escalation rates, and exception handling.
• Override covers who can pause the workflow, revert to manual review, or withdraw the tool from service.

For AI systems that touch patient care, governance should also cover provenance of model versions, validation of training and test data, logging of prompts and outputs where appropriate, and incident escalation when outputs conflict with clinical policy. CISA Secure by Design is useful here because it reinforces that safety and resilience are design responsibilities, not after-the-fact fixes.

Where the workflow uses autonomous or semi-autonomous actions, accountability should extend beyond the model itself to the surrounding controls: access restrictions, human review thresholds, audit logs, and rollback procedures. That is consistent with a broader governance view in NIST AI Risk Management Framework and the control-oriented structure of OWASP Top 10 for Large Language Model Applications, especially for prompt injection, output manipulation, and unsafe tool use. These controls tend to break down when the workflow is integrated into busy clinical operations without a named escalation path because staff then normalise exceptions and bypass review steps under time pressure.

Common Variations and Edge Cases

Tighter governance often increases review overhead and can slow clinical deployment, requiring organisations to balance patient safety against operational speed. That tradeoff is real, especially where AI supports high-volume triage, coding, or documentation and clinicians need rapid turnaround.

There is no universal standard for this yet, but best practice is evolving toward shared accountability with clear primary ownership. In regulated healthcare settings, the accountable party may differ depending on whether the AI workflow is advisory, administrative, or directly influences care decisions. Advisory tools may sit under clinical governance with lighter operational controls, while tools that shape treatment prioritisation need stronger approval, change control, and periodic revalidation.

Edge cases include vendor-hosted systems, embedded AI in EHR platforms, and agentic workflows that call external tools. In those cases, accountability must still remain inside the healthcare organisation even if operational tasks are outsourced. The vendor may be responsible for product defects or service commitments, but the organisation remains responsible for safe use in context. For cross-border deployments, privacy, retention, and data-processing responsibilities may also need alignment with GDPR and, where the system qualifies as a high-risk AI use case, the EU AI Act. The practical rule is simple: if the workflow can influence patient care, someone with clinical authority must be able to answer for it, even when the technology itself is highly automated.

Related resources from NHI Mgmt Group

• Who is accountable when a vendor-linked healthcare outage affects patient care?
• Who is accountable when poor IAM exposes patient data or disrupts care?
• Who is accountable when an AI agent completes a browser workflow incorrectly?
• Who is accountable when a pre-authentication RCE affects an AI service?